Bayer Shares Rise After Win in First Roundup Trial Since Supreme Court Ruling

A facts-only brief, written by a local AI model from this article in The Wall Street Journal, October 30, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.

A Missouri Circuit Court jury sided with Bayer’s Monsanto division on Thursday, rejecting design defect, fraud, and negligence claims brought by three plaintiffs regarding the Roundup weedkiller. This verdict marks the first trial win for the company since a U.S. Supreme Court ruling in June, which determined that Bayer cannot be held liable for failing to warn consumers about cancer risks when federal regulators did not mandate such labels. Bayer stated it will continue to defend the safety of its glyphosate-based herbicides in any remaining legal proceedings. The company is currently awaiting a separate court decision on its proposed $7.25 billion settlement, which aims to resolve years of litigation.

Background

• Bayer shares rose as much as 5.2% in European trading on Friday following the favorable verdict, contributing to a stock value increase of more than a third earlier in the year.
• J.P. Morgan analysts noted that the ruling suggests future plaintiffs will face significant hurdles in pursuing design defect and negligence claims.
• The Supreme Court decision in June eliminated a key argument used by plaintiffs concerning alleged failures to provide adequate warnings.

Read the full article at wsj.com

More from Friday, October 30: